

Dyskinesia - Pipeline Review, H1 2020

<https://marketpublishers.com/r/DC33722015DEN.html>

Date: March 2020

Pages: 249

Price: US\$ 2,000.00 (Single User License)

ID: DC33722015DEN

Abstracts

Dyskinesia - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H1 2020, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 17, 8, 26 and 5 respectively.

Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Dyskinesia - Overview

Dyskinesia - Therapeutics Development

Dyskinesia - Therapeutics Assessment

Dyskinesia - Companies Involved in Therapeutics Development

Dyskinesia - Drug Profiles

Dyskinesia - Dormant Projects

Dyskinesia - Discontinued Products

Dyskinesia - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Dyskinesia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H1 2020
Dyskinesia - Pipeline by Amaranthus Bioscience Holdings Inc, H1 2020
Dyskinesia - Pipeline by Astraea Therapeutics LLC, H1 2020
Dyskinesia - Pipeline by Bod Australia Ltd, H1 2020
Dyskinesia - Pipeline by Cadent Therapeutics Inc, H1 2020
Dyskinesia - Pipeline by Cannabis Science Inc, H1 2020
Dyskinesia - Pipeline by Cavion LLC, H1 2020
Dyskinesia - Pipeline by Cerevance Inc, H1 2020
Dyskinesia - Pipeline by Cerevel Therapeutics LLC, H1 2020
Dyskinesia - Pipeline by Clevexel Pharma SAS, H1 2020
Dyskinesia - Pipeline by Contera Pharma ApS, H1 2020
Dyskinesia - Pipeline by DanPET AB, H1 2020
Dyskinesia - Pipeline by EpiVax Inc, H1 2020
Dyskinesia - Dormant Projects, H1 2020
Dyskinesia - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Dyskinesia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Addex Therapeutics Ltd
Amarantus Bioscience Holdings Inc
Astraea Therapeutics LLC
Bod Australia Ltd
Cadent Therapeutics Inc
Cannabis Science Inc
Cavion LLC
Cerevance Inc
Cerevel Therapeutics LLC
Clevixel Pharma SAS
Contera Pharma ApS
DanPET AB
EpiVax Inc
GW Pharmaceuticals Plc
H. Lundbeck AS
Hua Medicine Shanghai Ltd
Ipsen SA
IRLAB Therapeutics AB
Junaxo Inc
Med-Life Discoveries LP
Medytox Inc

Melior Pharmaceuticals II LLC
Merz Pharma GmbH & Co KgaA
MitoDys Therapeutics Ltd
Motac Neuroscience Ltd
NeurAxon Pharma Inc
Neurim Pharmaceuticals Ltd
Neurocea Pharmaceuticals
Neurocrine Biosciences Inc
Neurolix Inc
Newron Pharmaceuticals SpA
Nissan Chemical Corp
OB Pharmaceuticals
Peptron Inc
PolyCore Therapeutics LLC
Praxis Precision Medicines Australia Pty Ltd
Prilenia Therapeutics Development Ltd
Revance Therapeutics Inc
Sage Therapeutics Inc
SalubRx Therapeutics Inc
Sinopia Biosciences Inc
SOM Biotech SL
Sosei Heptares
Teva Pharmaceutical Industries Ltd
Trevi Therapeutics Inc
Ultragenyx Pharmaceutical Inc
VistaGen Therapeutics Inc

I would like to order

Product name: Dyskinesia - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/DC33722015DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DC33722015DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970